Doctors Are Prescribing Retatrutide Before the FDA Approved It

Our Take

What this segment covers

• A CBS News investigation identified more than 120 websites selling or promoting retatrutide, including 50+ clinics staffed by licensed physicians and nurse practitioners.
• After being contacted by reporters, at least 21 clinics removed retatrutide from their sites or changed their wording.
• Poison-control exposures rose to an average of 95 cases per month in early 2026 — a 265% increase over late 2025.
• Why some providers defend prescribing it pre-approval — and why that breaks with the long-standing norm of waiting for FDA review.

Why this matters

Retatrutide's Phase 3 trial results are genuinely strong, which is precisely what's driving demand ahead of approval. But "promising in trials" and "safe to buy right now" are not the same thing. Anything sold as retatrutide today is unregulated: purity, dose, and even the identity of the compound are unverified, because no approved version exists.

The investigation matters because it documents a phenomenon with little modern precedent — an unapproved drug sold openly across the internet and through licensed clinics. That's the gap this hub exists to make clear: the science is moving fast, but the legal and safety picture has not caught up.

Disclaimer

Retatrutide is an investigational drug. It is not approved by the FDA and is not legally available outside clinical trials. This page is informational and is not medical advice or an offer to sell.